In rare cases, bisphosphonates, the class of medicines to which Fosamax belongs, have been linked to the death of jaw bone tissue. But the bisphosphonates mostly likely to cause this tissue death are the intravenous forms, such as Zometa or Aredia, which are given to cancer patients to retard the spread of tumors in the bone.